GB0307333D0 - Therapeutic agent - Google Patents

Therapeutic agent

Info

Publication number
GB0307333D0
GB0307333D0 GBGB0307333.5A GB0307333A GB0307333D0 GB 0307333 D0 GB0307333 D0 GB 0307333D0 GB 0307333 A GB0307333 A GB 0307333A GB 0307333 D0 GB0307333 D0 GB 0307333D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agent
therapeutic
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0307333.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0307333.5A priority Critical patent/GB0307333D0/en
Publication of GB0307333D0 publication Critical patent/GB0307333D0/en
Priority to PCT/GB2004/001286 priority patent/WO2004087120A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0307333.5A 2003-03-29 2003-03-29 Therapeutic agent Ceased GB0307333D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0307333.5A GB0307333D0 (en) 2003-03-29 2003-03-29 Therapeutic agent
PCT/GB2004/001286 WO2004087120A2 (fr) 2003-03-29 2004-03-23 Agent therapeutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0307333.5A GB0307333D0 (en) 2003-03-29 2003-03-29 Therapeutic agent

Publications (1)

Publication Number Publication Date
GB0307333D0 true GB0307333D0 (en) 2003-05-07

Family

ID=9955830

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0307333.5A Ceased GB0307333D0 (en) 2003-03-29 2003-03-29 Therapeutic agent

Country Status (2)

Country Link
GB (1) GB0307333D0 (fr)
WO (1) WO2004087120A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP1741432A1 (fr) * 2005-07-07 2007-01-10 Universitätsklinikum Freiburg L'inhibiteur de la tyrosine kinase Imatinib pour traiter l'hypertension

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
BE759842R (fr) * 1969-12-05 1971-06-03 Sandoz Sa Nouveaux derives de la 4-amino-quinazoline, leur preparation etmedicaments contenant ces
FR2077803B1 (fr) * 1970-02-16 1973-03-16 Innothera Lab Sa
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5614627A (en) * 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2392554A1 (fr) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibiteurs d'agregation de plaquettes induite par thrombine
ATE553782T1 (de) * 1999-12-22 2012-05-15 Scripps Research Inst Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1313727A1 (fr) * 2000-08-21 2003-05-28 AstraZeneca AB Derives de quinazoline
PE20021011A1 (es) * 2001-03-23 2003-02-01 Bayer Corp Derivados quinazolinicos como inhibidores de la rho-quinasa
ATE353889T1 (de) * 2001-03-23 2007-03-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren

Also Published As

Publication number Publication date
WO2004087120A3 (fr) 2005-01-27
WO2004087120A2 (fr) 2004-10-14

Similar Documents

Publication Publication Date Title
GB0303910D0 (en) Therapeutic agents
GB0308318D0 (en) Therapeutic agents
GB0314079D0 (en) Therapeutic agents
GB0314057D0 (en) Therapeutic agents
GB0313250D0 (en) Therapeutic agents
GB0310401D0 (en) Therapeutic agent
GB0323378D0 (en) Therapeutic agent
GB0314049D0 (en) Therapeutic agents
GB0314129D0 (en) Therapeutic agents
GB0311859D0 (en) Therapeutic agents
GB0311201D0 (en) Therapeutic agents
GB0301350D0 (en) Therapeutic agents
GB0314136D0 (en) Therapeutic agents
GB0314130D0 (en) Therapeutic agents
GB0314260D0 (en) Therapeutic agents
GB0314075D0 (en) Therapeutic agents
GB0314134D0 (en) Therapeutic agents
GB0304524D0 (en) Therapeutic agents
GB0314131D0 (en) Therapeutic agents
GB0314078D0 (en) Therapeutic agents
GB0307333D0 (en) Therapeutic agent
GB0310402D0 (en) Therapeutic agent
GB0307335D0 (en) Therapeutic agent
GB0303084D0 (en) Chrystalline therapeutic agent
EP1627632A4 (fr) Agent therapeutique

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)